Business
Exopharm (ASX:EX1) share price plunges 17% after animal testing results
The Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinical data from its osteoarthritis animal study, showing its two regenerative medical products had no effect on the rats studied.
At the time of writing, the Exopharm share price is down 15.7%, trading at 59 cents after hitting an intraday low of 55 cents.
Exopharm is a biopharmaceutical company focused on developing regenerative medicine. It’s currently investigating the therapeutic potential of two products, Plexaris and Cevaris, in treating osteoarthritis.
The company also aims to commercialise exosomes as therapeutic agents. Exosomes are membraneous structures that allow cells to communicate and have the potential to restore dying…
-
Business19 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business15 hours agoDicker Data rides the AI trend to double digit growth
-
Business23 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Noosa News16 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference